AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies
AbCellera (Nasdaq: ABCL) has partnered with Everest Medicines Limited to discover therapeutic antibodies for up to 10 selected targets, primarily in oncology. This multi-year collaboration aims to enhance Everest's drug pipeline by leveraging AbCellera’s advanced antibody discovery technology, including humanized antibodies and bispecifics. Everest will develop and commercialize the resulting antibodies, while AbCellera will receive research payments and potential royalties. This partnership seeks to accelerate the delivery of innovative therapies to patients in Asia and beyond.
- Partnership with Everest strengthens AbCellera's position in the antibody discovery market.
- Collaboration focuses on oncology, expanding Everest's pipeline of innovative medicines.
- AbCellera will receive milestone payments and royalties from successful products.
- None.
10-target partnership leverages AbCellera’s technology to accelerate Everest’s pipeline of novel, innovative medicines to patients
“We are proud to partner with Everest as they build a robust pipeline of innovative medicines for patients in
By partnering with AbCellera, Everest will benefit from an operating system that supports many antibody modalities to unlock new target classes and open new disease areas to therapeutic access. The collaboration will leverage the full breadth of AbCellera’s technology stack, including sourcing fully humanized antibodies from the Trianni Mouse®, sourcing single domain antibodies from camelids, and combining any two antibodies to create native bispecifics using the OrthoMabTM protein engineering platform.
“This collaboration will allow us to gain access to AbCellera’s cutting edge, AI-powered antibody discovery platform, which will greatly accelerate and increase the efficiency of our internal discovery efforts,” said
Under the terms of the agreement, Everest will have the rights to develop and commercialize antibodies resulting from the collaboration. AbCellera will receive research payments and is eligible to receive from Everest downstream clinical and commercial milestone payments and royalties on net sales of products.
About
About
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com.
AbCellera Forward-looking Statements
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the
Source:
View source version on businesswire.com: https://www.businesswire.com/news/home/20210922005854/en/
Everest Inquiries:
Media in US and
Media in
AbCellera Inquiries:
Media:
Business Development:
Investor Relations:
Source:
FAQ
What is the significance of the partnership between AbCellera and Everest Medicines?
What are the financial benefits for AbCellera from the collaboration with Everest?
How many targets will the AbCellera and Everest partnership focus on?
What technologies will be utilized in the AbCellera and Everest collaboration?